T5. LURASIDONE AND RISK FOR METABOLIC SYNDROME IN PATIENTS WITH SCHIZOPHRENIA: A COMPREHENSIVE DATABASE ANALYSIS

BACKGROUND: Patients with schizophrenia are at increased risk for developing metabolic syndrome, with an estimated prevalence of approximately 35–50% (Correll et al. Psychiatr Serv 2010;61:892–98; Vancampfort et al. World Psychiatry 2015;14:339–47). Treatment with atypical antipsychotic medications...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Schizophr Bull
Hoofdauteurs: Tocco, Michael, Pikalov, Andrei, Hsu, Jay, Cucchiaro, Josephine, Newcomer, John W, Loebel, Antony
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2018
Onderwerpen:
Abstracts
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5888403/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/schbul/sby016.281
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items